Literature DB >> 29470801

Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management.

Sebastiano Mercadante1,2,3.   

Abstract

The aim of this review is to present the way in which episodic breathlessness (EB) has been recognized over the years, with regard to definition, characteristics, and management of these acute episodes that have serious consequences for patients. EB is characterized by a sudden increase in intensity of dyspnea over a short duration of time, leading to high levels of anxiety. A significant aggravation of dyspnea may occur in patients with a background of dyspnea or intermittently even without basal breathlessness. Often, known precipitating factors may trigger EB. Flares of breathlessness are accompanied by degrees of psychological distress, although it is unclear whether psychological factors may precede or be induced by EB. In any case, there is a reinforcing circuit. The duration of EB ranges from 10-30 min. Given the specific temporal pattern, requiring rapid intervention, substances with a short onset of action are suitable to overlap this phenomenon. Short-onset opioids could provide a clinical effect overlapping the onset and duration of an episode, resembling what has been largely reported for breakthrough pain. Although data are still insufficient to suggest specific recommendations, strategies such as avoiding exertion, pacing or using devices, or keeping calm have been described. Few controlled studies have investigated the effects of different formulations of opioids. Some data were gathered from studies assessing the pre-emptive use of rapid onset opioids, such as transmucosal preparations of fentanyl, followed by a provocative test, while other studies attempted to reproduce real-life conditions, given as needed. All these trials were insufficiently powered to address the efficacy of fentanyl products over oral morphine or placebo, reflecting the difficulties in patient recruiting and finalizing the studies. Strategies to prevent the occurrence of EB should be taken into consideration, including optimization of the condition of persistent dyspnea or treating psychologic or environmental causes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29470801     DOI: 10.1007/s40265-018-0879-5

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  30 in total

Review 1.  Breathlessness--current and emerging mechanisms, measurement and management: a discussion from an European Association of Palliative Care workshop.

Authors:  David C Currow; Irene J Higginson; Miriam J Johnson
Journal:  Palliat Med       Date:  2013-07-09       Impact factor: 4.762

2.  Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Minjeong Park; Janet Williams; Diane Liu; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2016-07-09       Impact factor: 3.612

3.  Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial.

Authors:  David Hui; Angela Xu; Susan Frisbee-Hume; Gary Chisholm; Margarita Morgado; Suresh Reddy; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2013-07-03       Impact factor: 3.612

4.  Dyspnea in cancer patients: prevalence and associated factors.

Authors:  D J Dudgeon; L Kristjanson; J A Sloan; M Lertzman; K Clement
Journal:  J Pain Symptom Manage       Date:  2001-02       Impact factor: 3.612

5.  A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer.

Authors:  Miguel Ángel Cuervo Pinna; Eduardo Bruera; María José Redondo Moralo; Miguel Ángel Sánchez Correas; Rafael Mota Vargas
Journal:  Am J Hosp Palliat Care       Date:  2013-11-20       Impact factor: 2.500

6.  An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.

Authors:  Mark B Parshall; Richard M Schwartzstein; Lewis Adams; Robert B Banzett; Harold L Manning; Jean Bourbeau; Peter M Calverley; Audrey G Gift; Andrew Harver; Suzanne C Lareau; Donald A Mahler; Paula M Meek; Denis E O'Donnell
Journal:  Am J Respir Crit Care Med       Date:  2012-02-15       Impact factor: 21.405

7.  Identifying risk factors for imminent death in cancer patients with acute dyspnea.

Authors:  C P Escalante; C G Martin; L S Elting; K J Price; E F Manzullo; M A Weiser; T S Harle; S B Cantor; E B Rubenstein
Journal:  J Pain Symptom Manage       Date:  2000-11       Impact factor: 3.612

8.  Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline.

Authors:  Margaret A Charles; Liz Reymond; Fiona Israel
Journal:  J Pain Symptom Manage       Date:  2008-03-20       Impact factor: 3.612

Review 9.  Non-pharmacological interventions for breathlessness management in patients with lung cancer: a systematic review.

Authors:  I Zhao; P Yates
Journal:  Palliat Med       Date:  2008-09       Impact factor: 4.762

10.  "I Can Breathe Again!" Patients' Self-Management Strategies for Episodic Breathlessness in Advanced Disease, Derived From Qualitative Interviews.

Authors:  Steffen T Simon; Vera Weingärtner; Irene J Higginson; Hamid Benalia; Marjolein Gysels; Fliss E M Murtagh; James Spicer; Philipp Linde; Raymond Voltz; Claudia Bausewein
Journal:  J Pain Symptom Manage       Date:  2016-05-21       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.